HUMA

SEC source: 0001818382-24-000135 · wk-form4_1718655087.xml · derivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000141 · wk-form4_1718655156.xml · derivative · entry 1

Wallace Max N. · CIK 0001877453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000143 · wk-form4_1718655345.xml · derivative · entry 2

Sebelius Kathleen · CIK 0001654316 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000142 · wk-form4_1718655168.xml · derivative · entry 1

Windham-Bannister Susan Richards · CIK 0001713760 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000139 · wk-form4_1718655133.xml · derivative · entry 1

Pope Todd · CIK 0001584367 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000134 · wk-form4_1718655077.xml · derivative · entry 1

Constantino Michael T. · CIK 0001817285 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028.

SEC source: 0001818382-24-000101 · wk-form4_1718311705.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,559,140

F2 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000100 · wk-form4_1718311640.xml · nonDerivative · entry 3

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,559,140

F2 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000101 · wk-form4_1718311705.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,830,658

F2 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000101 · wk-form4_1718311705.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,907,288

F1 · shares: Shares were sold in a private transaction to a trust controlled by family members of the Reporting Person. Said family members do not share the same household as the Reporting Person.

SEC source: 0001818382-24-000100 · wk-form4_1718311640.xml · nonDerivative · entry 2

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,830,658

F2 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000100 · wk-form4_1718311640.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 4,907,288

F1 · shares: Shares were sold in a private transaction to a trust controlled by family members of Laura E. Niklason, the Reporting Person's spouse. Said family members do not share the same household as the Reporting Person's spouse.

SEC source: 0001818382-24-000087 · wk-form4_1717542316.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,832

F1 · shares: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 93,213 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $7,015.79, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.3497 to $6.3499. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 4

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,189,288

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F6 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000086 · wk-form4_1717542215.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 240,832

F1 · shares: This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 93,213 shares of the Issuer's common stock on May 31, 2024. The Reporting Person's spouse has paid the Issuer $7,015.79, representing the full amount of profit realized in connection with this purchase.

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.3497 to $6.3499. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000083 · wk-form4_1717541738.xml · nonDerivative · entry 4

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,189,288

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F6 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000076 · wk-form4_1717446687.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,470

SEC source: 0001818382-24-000075 · wk-form4_1717446451.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 238,470

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 3

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,191,140

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F5 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000083 · wk-form4_1717541738.xml · nonDerivative · entry 3

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,191,140

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F5 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 6

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,381,354

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F3 · shares: A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Dr. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000084 · wk-form4_1717541869.xml · nonDerivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,474,567

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000083 · wk-form4_1717541738.xml · nonDerivative · entry 2

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,381,354

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F3 · shares: A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Laura E. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person's spouse has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale.

F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000083 · wk-form4_1717541738.xml · nonDerivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ayabudge LLC

Disclosed balance after: 5,474,567

F1 · shares: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · derivative · entry 8

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,834

Underlying: Common Stock · 48,166 shares

Expires 2032-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · derivative · entry 7

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,779 shares

Expires 2025-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 5

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.31 to $8.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 4

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,791

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 3

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

F1 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.36 to $8.44. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 2

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 1

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,625

SEC source: 0001818382-24-000066 · wk-form4_1716322109.xml · derivative · entry 2

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

Underlying: Common Stock · 600 shares

Expires 2032-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000066 · wk-form4_1716322109.xml · nonDerivative · entry 1

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000067 · wk-form4_1716322124.xml · nonDerivative · entry 2

Wallace Max N. · CIK 0001877453 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Max N Wallace IRA

Disclosed balance after: 3,990

SEC source: 0001818382-24-000067 · wk-form4_1716322124.xml · nonDerivative · entry 1

Wallace Max N. · CIK 0001877453 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Max Wallace SEP IRA

Disclosed balance after: 4,015

SEC source: 0001818382-24-000061 · wk-form4_1716235842.xml · derivative · entry 2

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,400

Underlying: Common Stock · 600 shares

Expires 2032-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000061 · wk-form4_1716235842.xml · nonDerivative · entry 1

Green Charles Bruce · CIK 0001945398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001818382-24-000058 · wk-form4_1715815434.xml · nonDerivative · entry 2

Binder Gordon M · CIK 0001291957 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

F2 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.64 to $6.96. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-24-000058 · wk-form4_1715815434.xml · nonDerivative · entry 1

Binder Gordon M · CIK 0001291957 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Binder Trust dated 15 July 2003

Disclosed balance after: 50,000

F1 · price: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $6.44 to $6.59. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001818382-23-000191 · wk-form4_1702415348.xml · derivative · entry 2

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,100

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F2 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-23-000193 · wk-form4_1702415371.xml · derivative · entry 2

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,100

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F2 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-23-000192 · wk-form4_1702415359.xml · derivative · entry 2

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 2,100

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F2 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-23-000196 · wk-form4_1702415411.xml · derivative · entry 2

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,100

Underlying: Common Stock · 525 shares

Expires 2030-12-14

F2 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.

SEC source: 0001818382-23-000197 · wk-form4_1702415423.xml · derivative · entry 1

Scheessele William John · CIK 0001879378 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,000

Underlying: Common Stock · 276,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

SEC source: 0001818382-23-000191 · wk-form4_1702415348.xml · derivative · entry 1

Niklason Laura E · CIK 0001878075 · Director · President, CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 803,000

Underlying: Common Stock · 803,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

SEC source: 0001818382-23-000193 · wk-form4_1702415371.xml · derivative · entry 1

Sander Dale A. · CIK 0001878193 · CFO and Chief Corp. Deve. Off.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301,000

Underlying: Common Stock · 301,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

SEC source: 0001818382-23-000192 · wk-form4_1702415359.xml · derivative · entry 1

Dougan Brady W · CIK 0001878020 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 803,000

Underlying: Common Stock · 803,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

SEC source: 0001818382-23-000196 · wk-form4_1702415411.xml · derivative · entry 1

Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,000

Underlying: Common Stock · 290,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

SEC source: 0001818382-23-000195 · wk-form4_1702415399.xml · derivative · entry 1

Parikh Shamik J · CIK 0001916853 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,000

Underlying: Common Stock · 283,000 shares

Expires 2033-12-08

F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.